feedback

Faculty

Leisha A. Emens, MD, PhD
Associate Professor of Oncology
Johns Hopkins University School of Medicine
Baltimore, MD

Activity Planners

Julie Blum, PhD
Senior Clinical Content Manager
Med-IQ
Baltimore, MD

Rebecca L. Julian, MS, ELS
Senior Managing Editor
Med-IQ
Baltimore, MD

Amy Sison
Director of Continuing Medical Education
Med-IQ
Baltimore, MD

Writer

Lori K. Pender, PharmD, MPH, ELS
Seattle, WA

Provided By

Activity Details

Free
CME

0.75 AMA PRA Category 1 Credit

Released: April 18, 2017

Expires: April 17, 2018

45 minutes to complete

No registration required

Learning Objectives

Upon completion, participants should be able to:

  • Develop individualized treatment plans for patients with locoregional and metastatic HER2-positive breast cancer based on the latest clinical evidence and practice guideline recommendations
  • Assess clinically relevant data for immunotherapies in clinical development for metastatic triple-negative breast cancer

Target Audience

This activity is intended for international oncologists.

Statement of Educational Need

Breast cancer represents a heterogeneous family of malignancies with distinct biological subtypes that are associated with unique prognostic and etiologic features. Treatment choice depends greatly on tumor expression of three key biomarkers in this setting: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Advancing insights related to the characterization of distinct breast cancer subtypes based on their expression profiles, together with the development of agents that specifically target these genetic alterations, have facilitated greater individualization of treatment across the spectrum of disease. However, with these therapeutic advances come many practical questions related to optimal timing, selection, sequencing, and duration of available therapies, particularly for patients with advanced HER2-positive disease, both prior to surgery and in the recurrent setting.

Furthermore, oncologists are challenged with remaining up-to-date on the rapidly evolving evidence base related to the role of the immune system in the growth and progression of cancer, as well as the safety and efficacy of novel immunotherapies in the treatment of advanced disease. Although breast cancer has long been considered to be immunologically silent, promising data are beginning to emerge in trials of patients with metastatic triple-negative breast cancer (TNBC), a particularly aggressive disease subtype for which available treatment options are limited and outcomes are poor.

Accreditation Statement for Physicians

Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Med-IQ designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Medium/Method of Participation

This CME activity consists of a 0.75-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

The evaluation, attestation, and post-test can be accessed by continuing on with this activity.

Disclosure Policy

Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Disclosure Statement

The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

Leisha A. Emens, MD, PhD
Royalty: Aduro Biotech
Consulting fees/advisory boards: Amgen, AstraZeneca, Celgene Corporation, Peregrine, Syndax, Vaccinex
Contracted research: Aduro Biotech, AstraZeneca, Corvus Pharmaceuticals, EMD Serono, Inc., F. Hoffman-La Roche Ltd., Genentech, MaxCyte, Inc., Merck & Co., Inc.

The writer, peer reviewers, and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content

Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information

For CME questions or comments about this activity, please contact Med-IQ.
Call (toll-free) 866 858 7434 or e-mail info@med-iq.com.

Hardware / Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

ADA Statement

Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Disclaimer

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality

Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: www.med-iq.com/privacy-policy.html.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Hoffmann-La Roche.

Copyright

© 2017 Med-IQ®. All rights reserved.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.